Crinetics Pharmaceuticals, Inc.
CRNX
$37.48
$0.571.54%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 2,277.50% | 640.71% | 47.74% | 0.51% | -61.50% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 2,277.50% | 640.71% | 47.74% | 0.51% | -61.50% |
| Cost of Revenue | 35.78% | 38.72% | 43.07% | 41.72% | 43.43% |
| Gross Profit | -29.28% | -36.10% | -43.05% | -42.01% | -44.57% |
| SG&A Expenses | 80.57% | 91.84% | 87.07% | 78.25% | 71.48% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 49.36% | 54.30% | 55.74% | 51.95% | 50.92% |
| Operating Income | -44.86% | -52.50% | -55.77% | -52.21% | -51.81% |
| Income Before Tax | -51.17% | -55.87% | -52.24% | -43.05% | -39.41% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -51.22% | -55.93% | -52.24% | -43.05% | -39.41% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -51.22% | -55.93% | -52.24% | -43.05% | -39.41% |
| EBIT | -44.86% | -52.50% | -55.77% | -52.21% | -51.81% |
| EBITDA | -45.01% | -52.61% | -55.71% | -51.93% | -51.29% |
| EPS Basic | -34.49% | -33.52% | -21.96% | -9.10% | -1.20% |
| Normalized Basic EPS | -34.45% | -33.48% | -21.97% | -9.09% | -1.20% |
| EPS Diluted | -34.49% | -33.52% | -21.96% | -9.10% | -1.20% |
| Normalized Diluted EPS | -34.45% | -33.48% | -21.97% | -9.09% | -1.20% |
| Average Basic Shares Outstanding | 12.66% | 16.51% | 24.81% | 30.24% | 37.19% |
| Average Diluted Shares Outstanding | 12.66% | 16.51% | 24.81% | 30.24% | 37.19% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |